CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with B-ALL (a type of blood cancer affecting B cells) and achieved complete remission after standard chemotherapy
- You completed two cycles of intensive consolidation chemotherapy and tests show no measurable disease (MRD negative)
- You are between 18 and 85 years old and in good enough health (ECOG score 0–2)
- You cannot or do not want to receive blinatumomab (a different immunotherapy) or stem cell transplant
- You have adequate blood counts, organ function (liver, kidney, heart), and no active infections or HIV/hepatitis B
- You have not received any prior CAR-T or gene-modified T-cell therapies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
This trial tests an engineered immune-cell treatment (GC019F CAR-T) for adults with B-cell ALL that has come back or did not respond to prior therapy. If it works, it may help your immune system attack leukemia cells by targeting CD19.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.